American College of Clinical Pharmacy
      Search      Cart
         

PSAP in JACCP - Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants and Part II: Interactive Case: Rapid Sequence Intubation - 2023 December


Member Price:
$29.95
Nonmember Price:
$29.95

Faculty Information

PSAP in JACCP features are developed from activities presented as part of the Pharmacotherapy Self-Assessment Program (PSAP).

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

This feature was developed from an interactive case presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

  • Interactive case: Click here to access the interactive case.
Part II: Interactive Case: Rapid Sequence Intubation

This feature was developed from an interactive case presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

  • Interactive case: Click here to access the interactive case.

Author - Reviewer Information

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Author: Emily J. Owen, Pharm.D., MS, BCPS, BCCCP
Reviewed by: Jenna Goetz, Pharm.D., BCPS, BCCCP; and Rizah Anwar Assadi, Pharm.D., BCPS

Part II: Interactive Case: Rapid Sequence Intubation

Author: Madeline Jane Foertsch, Pharm.D., BCCCP
Reviewed by: Matthew J. Campbell, Pharm.D., BCPS, BCCCP; and Andrea Boland, Pharm.D., BCPS

Target Audience and Learning Objectives

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

  1. Classify antithrombotic agents according to labeled indication, mechanism of action, and pharmacokinetic properties.
  2. Assess life-threatening bleeding events caused by antithrombotic agents for treatment.
  3. Evaluate the risk-benefit of treatments for life-threatening bleeding in the setting of an antithrombotic agent.
  4. Develop an appropriate drug-dose regimen for a patient with life-threatening bleeding associated with an antithrombotic agent.
Part II: Interactive Case: Rapid Sequence Intubation

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

  1. Assess the pharmacologic properties and indication or pretreatment agents used in rapid sequence intubation (RSI).
  2. Evaluate the pharmacologic properties of induction agents used in RSI.
  3. Distinguish the pharmacologic properties of neuromuscular blocking agents used in RSI.
  4. Design appropriate patient-specific RSI regimens, and incorporate patient disease state interactions into them.

Disclosure of Potential Conflicts of Interest

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Emily Owen: Consultancies (Mallinckrodt); Honoraria (Mallinckrodt)
Nothing to disclose: Rizah Anwar Assadi, Jenna Goetz

Part II: Interactive Case: Rapid Sequence Intubation

Matthew J. Campbell: Grants (Spero Therapeutics)
Andrea Boland: Consultancies (Arkansas Association of Hospital Pharmacists)
Nothing to disclose: Madeline Jane Foertsch

Continuing Pharmacy Education and Recertification Instructions

Available CPE/Recertification credits: Anyone who purchases, successfully completes, and passes the required posttests for this feature can earn up to 3.0 contact hours of CPE/Recertification credit.

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Universal Activity Number: 0217-0000-23-223-H01-P
1.5 CPE contact hours
Application-Based Activity

Part II: Interactive Case: Rapid Sequence Intubation

Universal Activity Number: 0217-0000-23-224-H01-P
1.5 CPE contact hours
Application-Based Activity

Release date: December 8, 2023
BCPS posttest submission deadline: 11:59 p.m. (Central) on June 8, 2024.
ACPE posttest submission deadline: 11:59 p.m. (Central) on December 8, 2026.

TO EARN CPE/RECERTIFICATION CREDIT FROM THIS FEATURE
Posttest access: Purchase the required posttests (see below); then go to www.accp.com and sign in with your e-mail address and password. PSAP in JACCP features are listed under My Products on your My Account page.
Technical support is available from 8 a.m. to 5 p.m. (Central) weekdays by e-mail at [email protected].

Release Date: December 08, 2023
BCPS Deadline: June 08, 2024
ACPE Deadline: December 08, 2026

Publication Year: 2023
Format: Online Test

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American College of Clinical Pharmacy is approved by BPS as a provider for the recertification of BCPS.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.


Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.